Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ferring Launches Novel Prostate Cancer Treatment Degarelix

Executive Summary

Swiss-drug maker Ferring launched its rapid onset prostate cancer treatment degarelix in the U.S. and Europe in March, marking the firm's first global launch

You may also be interested in...

Stelara And Firmagon Suffer Setbacks In Draft NICE Appraisals

Janssen has until Jan. 17 to argue the cost-effectiveness of Stelara in the additional indication, psoriatic arthritis, while Ferring faces a restricted indication recommendation for Firmagon.

Ferring Degarelix Prostate Cancer Drug To Launch In First Quarter

FDA approves the gonadotropin-releasing hormone receptor antagonist, which hasn’t shown the initial surge in testosterone seen with other therapies.

Ferring’s Degarelix Effectively Cut Testosterone Levels In Phase III Prostate Cancer Trial

However, more details are needed before clinicians get excited about this drug, one oncologist tells “The Pink Sheet” DAILY.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts